Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ladiratuzumab Vedotin

Antibody-drug conjugate · Cytotoxic, directed at SLC39A6 (LIV-1) (SLC39A6) · developed by Seagen

Phase 1/2 Most advanced trial

1 Registered trials

What is Ladiratuzumab Vedotin?

Ladiratuzumab vedotin is an antibody-drug conjugate composed of a humanized monoclonal antibody against SLC39A6 (LIV-1) conjugated to monomethyl auristatin E (MMAE). Upon internalization by LIV-1-positive tumor cells, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis. It is studied in metastatic breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: SGN-LIV1A
Drug type: Antibody-drug conjugate
Targets: SLC39A6 (LIV-1) (SLC39A6)
Mechanism: Cytotoxic, directed at SLC39A6 (LIV-1) (SLC39A6)
Pathways: tubulin polymerization inhibition, G2/M cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: Seagen Inc.
In trials of: GILD
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: VM4G5D1A60

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03424005	Phase 1/2	Metastatic Breast Cancer	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Breast Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z